EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review

Amanda L King iD, Tamara Vasilj iD, Diane Cooper, Elizabeth Vera iD, Sefanit Berhanu, Morgan Johnson iD, Ciara Locke, Bennett Mciver iD, Ethan Basch iD, Joseph C Cappelleri iD, Amylou Dueck iD, Mark R Gilbert iD und 6 weitere

JNCI Cancer Spectrum · 2025

DOI: 10.1093/jncics/pkaf036 ↗

Kurz gefasst

Scoping Review in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Amanda L King und 17 weiteren Autor:innen. Beteiligte Einrichtung: Office of Patient-Centered Outcomes Research, National Cancer Institute, Bethesda, MD, United States. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Immunotherapy, Molecular Targeted Therapy. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients’ self-report of their symptoms can provide important data for the evaluation of treatment benefit and tolerability of oncology drugs. Contemporary treatment approaches, including immunotherapy and molecular targeted therapies, have unique toxicities based on their novel mechanisms of action. This scoping review aimed to summarize evidence from existing reviews and clinical practice guidelines to examine the type and prevalence of toxicities including symptomatic adverse events (sympAEs) for adult cancer patients to inform clinical care and therapeutic trials.

Methods

A systematic search of PubMed, Web of Science, and Embase was performed using predefined eligibility criteria. Thirty-one literature reviews and 3 clinical practice guidelines met inclusion criteria and were selected for review and data abstraction.

Results

Findings from this scoping review demonstrated several leading sympAEs that were reported across immunotherapy and targeted therapy drugs, including fatigue, diarrhea, and rash. In addition to these more prevalent sympAEs, there were some less frequently reported class-specific sympAEs, which had potential for significant harm or disability to the patient if not properly identified and treated. Many studies reported toxicities as AEs or syndromes solely using data reported by clinicians without additional self-report from patients.

Conclusion

We identified several core sympAEs experienced by patients participating in oncology trials using immunotherapy and targeted therapy agents, which has implications for future trial design and drug labeling. Future cancer trials should assess patient-reported sympAEs based on the identified drug mechanism to inform the tolerability of these newer agents and enhance patient safety during trial participation and clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsImmunotherapyMolecular Targeted TherapyDrug-Related Side Effects and Adverse ReactionsHumansAdultPrevalenceFatigueDiarrheaClinical Trials as TopicExanthemaSelf Report

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Office of Patient-Centered Outcomes Research, National Cancer Institute, Bethesda, MD, United States.
  • Immune Deficiency Cellular Therapy Program, National Cancer Institute, Bethesda, MD, United States.
  • National Institutes of Health Library, National Cancer Institute, Bethesda, MD, United States.
  • Neuro-Oncology Branch, National Cancer Institute, Bethesda, MD, United States.
  • Division of Oncology, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States.
  • Statistical Research and Data Science Center, Pfizer Inc, Groton, CT, United States.

ORCID-Profile: Amanda L King, Tamara Vasilj, Elizabeth Vera, Morgan Johnson, Bennett Mciver, Ethan Basch, Joseph C Cappelleri, Amylou Dueck, Mark R Gilbert, Lee Jones, Yuelin Li, Lori M Minasian, Bryce B Reeve, Terri S Armstrong, Tito Mendoza

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

King, A. L., Vasilj, T., Cooper, D., Vera, E., Berhanu, S., Johnson, M., Locke, C., Mciver, B., Basch, E., Cappelleri, J. C., Dueck, A., Gilbert, M. R., Jones, L., Li, Y., Minasian, L. M., Reeve, B. B., Armstrong, T. S., & Mendoza, T. (2025). Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf036

Vancouver

King AL, Vasilj T, Cooper D, Vera E, Berhanu S, Johnson M, et al. Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkaf036

BibTeX
@article{King2025,
  author = {King, Amanda L and Vasilj, Tamara and Cooper, Diane and Vera, Elizabeth and Berhanu, Sefanit and Johnson, Morgan and Locke, Ciara and Mciver, Bennett and Basch, Ethan and Cappelleri, Joseph C and Dueck, Amylou and Gilbert, Mark R and Jones, Lee and Li, Yuelin and Minasian, Lori M and Reeve, Bryce B and Armstrong, Terri S and Mendoza, Tito},
  title = {Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review},
  journal = {JNCI Cancer Spectrum},
  year = {2025},
  doi = {10.1093/jncics/pkaf036}
}
Kostenlos starten →